Kleinert Regina, Lange Claudia, Steup Achim, Black Peter, Goldberg Jutta, Desjardins Paul
Grunenthal GmbH, Zieglerstr. 6 52078, Aachen, Germany.
Anesth Analg. 2008 Dec;107(6):2048-55. doi: 10.1213/ane.0b013e31818881ca.
Tapentadol is a novel, centrally acting analgesic with two modes of action, combining mu-opioid agonism and norepinephrine reuptake inhibition in a single molecule. We compared the efficacy and tolerability of tapentadol and a standard dose of morphine with placebo in a model of moderate-to-severe postoperative dental pain.
Patients undergoing mandibular third molar extraction and experiencing moderate-to-severe pain postsurgery were randomized to receive single, oral doses of tapentadol HCl (25, 50, 75, 100, or 200 mg), morphine sulfate (60 mg), ibuprofen (400 mg; used to establish model sensitivity), or placebo. Mean total pain relief over 8 h (TOTPAR-8) was the primary end point. Secondary end points included mean total pain relief over 4 h (TOTPAR-4) and onset of analgesia. Pairwise comparisons of study drug to placebo were assessed using the Fisher least significant difference test. Adverse events were recorded.
Four hundred patients were randomized to treatment and completed the study. Compared with placebo, mean TOTPAR-8 was significantly greater for tapentadol HCl 50 mg (P = 0.041), 75 mg (P = 0.001), 100 mg (P < 0.001), and 200 mg (P < 0.001); morphine sulfate 60 mg (P < 0.001); and ibuprofen 400 mg (P < 0.001) in a nonparametric analysis of the primary end point. The significantly higher TOTPAR-8 score for ibuprofen compared with placebo established the sensitivity of the model. Mean TOTPAR-4 was higher and onset of action appeared more rapid for tapentadol HCl 200 mg than morphine sulfate 60 mg. Pain relief scores with morphine sulfate 60 mg were between those of tapentadol HCl 100 and 200 mg. The incidence of nausea and vomiting appeared to be lower with all doses of tapentadol HCl compared with morphine sulfate 60 mg, but was not statistically significant.
Single oral doses of tapentadol 75 mg or higher effectively reduced moderate-to-severe postoperative dental pain in a dose-related fashion and were well-tolerated relative to morphine. These data suggest that tapentadol is a highly effective, centrally acting analgesic with a favorable side effect profile and rapid onset of action.
曲马多是一种新型的中枢性镇痛药,具有两种作用模式,在单一分子中结合了μ-阿片受体激动作用和去甲肾上腺素再摄取抑制作用。我们在中重度术后牙痛模型中比较了曲马多和标准剂量吗啡与安慰剂的疗效和耐受性。
接受下颌第三磨牙拔除术且术后有中重度疼痛的患者被随机分配接受单次口服盐酸曲马多(25、50、75、100或200mg)、硫酸吗啡(60mg)、布洛芬(400mg;用于确定模型敏感性)或安慰剂。8小时内的平均总疼痛缓解(TOTPAR-8)是主要终点。次要终点包括4小时内的平均总疼痛缓解(TOTPAR-4)和镇痛起效时间。使用Fisher最小显著差异检验评估研究药物与安慰剂的两两比较。记录不良事件。
400名患者被随机分配接受治疗并完成研究。在对主要终点的非参数分析中,与安慰剂相比,盐酸曲马多50mg(P = 0.041)、75mg(P = 0.001)、100mg(P < 0.001)和200mg(P < 0.001);硫酸吗啡60mg(P < 0.001);以及布洛芬400mg(P < 0.001)的平均TOTPAR-8显著更高。布洛芬与安慰剂相比显著更高的TOTPAR-8评分确立了模型的敏感性。盐酸曲马多200mg的平均TOTPAR-4更高,起效似乎比硫酸吗啡60mg更快。硫酸吗啡60mg的疼痛缓解评分介于盐酸曲马多100mg和200mg之间。与硫酸吗啡60mg相比,所有剂量的盐酸曲马多恶心和呕吐的发生率似乎更低,但无统计学意义。
单次口服75mg或更高剂量的曲马多能以剂量相关的方式有效减轻中重度术后牙痛,相对于吗啡耐受性良好。这些数据表明曲马多是一种高效的中枢性镇痛药,具有良好的副作用谱和快速起效。